Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

13.79
+0.15001.10%
Post-market: 13.790.00000.00%19:01 EDT
Volume:886.56K
Turnover:12.07M
Market Cap:1.15B
PE:-4.35
High:13.97
Open:13.60
Low:13.25
Close:13.64
52wk High:19.11
52wk Low:3.91
Shares:83.43M
Float Shares:59.91M
Volume Ratio:0.71
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1700
EPS(LYR):-3.1667
ROE:-72.19%
ROA:-38.89%
PB:3.76
PE(LYR):-4.35

Loading ...

Stock Track | EyePoint Plummets 5.77% Intraday After Q4 Earnings Miss Estimates

Stock Track
·
Mar 04

EyePoint Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 04

EyePoint reports Q4 EPS (81c), consensus (75c)

TIPRANKS
·
Mar 04

EyePoint expects cash to fund operations into Q4 2027

TIPRANKS
·
Mar 04

Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss

MT Newswires Live
·
Mar 04

EyePoint Q4 net revenue USD 0.6 million -94.7%

Reuters
·
Mar 04

EyePoint Pharmaceuticals Q4 EPS $(0.81) Misses $(0.73) Estimate, Sales $620.000K Miss $1.010M Estimate

Benzinga
·
Mar 04

EyePoint Pharmaceuticals Q4 Product Sales USD 299 Thousand

THOMSON REUTERS
·
Mar 04

EyePoint Pharmaceuticals Q4 Basic EPS USD -0.81

THOMSON REUTERS
·
Mar 04

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire
·
Mar 04

U.S. Earnings Preview: Before Market Open March 4

Dow Jones
·
Mar 04

Analysts’ Top Healthcare Picks: EyePoint Pharmaceuticals (EYPT), Astrana Health (ASTH)

TIPRANKS
·
Mar 03

BRIEF-Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027

Reuters
·
Mar 02

EyePoint doses first patients in Phase 3 DURAVYU trials for diabetic macular edema

Reuters
·
Mar 02

EyePoint Inc: Topline Data for Duravyu in Dme Anticipated in 2H 2027

THOMSON REUTERS
·
Mar 02

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of Duravyu™ for the Treatment of Diabetic Macular Edema

THOMSON REUTERS
·
Mar 02

EyePoint Inc. to Report Fourth-Quarter and Full-Year Financial Results on Conference Call

Reuters
·
Feb 25

EyePoint management to participate in upcoming investor conferences

Reuters
·
Feb 24

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

TIPRANKS
·
Feb 24

EyePoint Chief Medical Officer Ramiro Ribeiro Disposes of Common Shares

Reuters
·
Feb 19